Experts will discuss how they use new CRISPR technologies to advance their cell and gene therapy research.

Join us to learn about adoptive cell therapies from leading experts in the field of cancer immunology. 

As the first clinical data become available on treating coronavirus patients with the cells, scientists are equivocal about the rationale for the intervention.

The immunotherapy induces a form of cell death in leukemia cells in mice that triggers cytokine release syndrome, a dangerous inflammatory reaction that occurs in some patients.

To advance the possibility of off-the-shelf cardiac cell therapies, scientists devise an engineered cardiac stem cell that avoids stimulating a detrimental immune attack.

Several early-stage clinical trials indicate that implanting patients with the cells is safe. But whether they can alleviate neurological problems remains to be seen.

The decision may facilitate the agency cracking down more effectively on the unproven interventions these companies sell.

Uncertainties about the cells’ risk profiles and the potential for hyping unproven therapies mean scientists and the media must tread carefully.

From disastrous scientific setbacks to the upending of scientific dogma and the end of a 40-year search for a protein